{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:09:27Z","timestamp":1792501767164,"version":"4.5.0"},"publisher-location":"Cham","reference-count":144,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319675756","type":"print"},{"value":"9783319675770","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-67577-0_4","type":"book-chapter","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T06:03:18Z","timestamp":1514008998000},"page":"51-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["The Role of Tumor Microenvironment in Cancer Immunotherapy"],"prefix":"10.1007","author":[{"given":"Timothy","family":"Frankel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna Perusina","family":"Lanfranca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,24]]},"reference":[{"issue":"7480","key":"4_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/504S1a","volume":"504","author":"L Gravitz","year":"2013","unstructured":"Gravitz L. Cancer immunotherapy. Nature. 2013;504(7480):S1.","journal-title":"Nature"},{"issue":"10","key":"4_CR2","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1056\/NEJMc081511","volume":"359","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Dudley ME, Restifo NP. Cancer immunotherapy. N Engl J Med. 2008;359(10):1072.","journal-title":"N Engl J Med"},{"issue":"2","key":"4_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","volume":"25","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Woo SR, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25(2):268\u201376.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"4_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0167-5699(00)01692-3","volume":"21","author":"B Seliger","year":"2000","unstructured":"Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000;21(9):455\u201364.","journal-title":"Immunol Today"},{"issue":"3","key":"4_CR5","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.4049\/jimmunol.173.3.1526","volume":"173","author":"TL Whiteside","year":"2004","unstructured":"Whiteside TL, Stanson J, Shurin MR, et al. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol. 2004;173(3):1526\u201334.","journal-title":"J Immunol"},{"issue":"45","key":"4_CR6","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904\u201312.","journal-title":"Oncogene"},{"key":"4_CR7","first-page":"29","volume":"6","author":"E Heninger","year":"2015","unstructured":"Heninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol. 2015;6:29.","journal-title":"Front Immunol"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2407-2-29","volume":"2","author":"J Yu","year":"2002","unstructured":"Yu J, Ni M, Xu J, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer. 2002;2:29.","journal-title":"BMC Cancer"},{"issue":"12","key":"4_CR9","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1158\/0008-5472.CAN-10-2442","volume":"71","author":"M Rao","year":"2011","unstructured":"Rao M, Chinnasamy N, Hong JA, et al. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res. 2011;71(12):4192\u2013204.","journal-title":"Cancer Res"},{"issue":"10","key":"4_CR10","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/bjc.2011.428","volume":"105","author":"J Simova","year":"2011","unstructured":"Simova J, Pollakova V, Indrova M, et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. Br J Cancer. 2011;105(10):1533\u201341.","journal-title":"Br J Cancer"},{"issue":"5","key":"4_CR11","doi-asserted-by":"publisher","first-page":"e62924","DOI":"10.1371\/journal.pone.0062924","volume":"8","author":"LX Wang","year":"2013","unstructured":"Wang LX, Mei ZY, Zhou JH, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One. 2013;8(5):e62924.","journal-title":"PLoS One"},{"issue":"1","key":"4_CR12","doi-asserted-by":"publisher","first-page":"e27414","DOI":"10.4161\/onci.27414","volume":"3","author":"AC West","year":"2014","unstructured":"West AC, Smyth MJ, Johnstone RW. The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology. 2014;3(1):e27414.","journal-title":"Oncoimmunology"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1101\/sqb.2013.78.020255","volume":"78","author":"A Iannello","year":"2013","unstructured":"Iannello A, Raulet DH. Immune surveillance of unhealthy cells by natural killer cells. Cold Spring Harb Symp Quant Biol. 2013;78:249\u201357.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"1","key":"4_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2011.12.004","volume":"22","author":"MT Chow","year":"2012","unstructured":"Chow MT, Moller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22(1):23\u201332.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"4_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000327014","volume":"3","author":"A Groth","year":"2011","unstructured":"Groth A, Kloss S, von Strandmann EP, et al. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun. 2011;3(4):344\u201354.","journal-title":"J Innate Immun"},{"issue":"5","key":"4_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/00002371-200409000-00001","volume":"27","author":"F Melchionda","year":"2004","unstructured":"Melchionda F, McKirdy MK, Medeiros F, et al. Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother. 2004;27(5):329\u201338.","journal-title":"J Immunother"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1745-6150-7-31","volume":"7","author":"M Al-Tameemi","year":"2012","unstructured":"Al-Tameemi M, Chaplain M, d\u2019Onofrio A. Evasion of tumours from the control of the immune system: consequences of brief encounters. Biol Direct. 2012;7:31.","journal-title":"Biol Direct"},{"issue":"12","key":"4_CR18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/nm1201-1339","volume":"7","author":"W Zou","year":"2001","unstructured":"Zou W, Machelon V, Coulomb-L\u2019Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001;7(12):1339\u201346.","journal-title":"Nat Med"},{"issue":"5","key":"4_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562\u20137.","journal-title":"Nat Med"},{"issue":"9","key":"4_CR20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"4_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20050930","volume":"203","author":"I Kryczek","year":"2006","unstructured":"Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871\u201381.","journal-title":"J Exp Med"},{"issue":"3","key":"4_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","volume":"39","author":"TX Cui","year":"2013","unstructured":"Cui TX, Kryczek I, Zhao L, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611\u201321.","journal-title":"Immunity"},{"issue":"10","key":"4_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1172\/JCI17656","volume":"111","author":"XF Bai","year":"2003","unstructured":"Bai XF, Liu J, Li O, et al. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest. 2003;111(10):1487\u201396.","journal-title":"J Clin Invest"},{"issue":"2","key":"4_CR24","first-page":"487","volume":"25","author":"J Bubenik","year":"2004","unstructured":"Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol. 2004;25(2):487\u201391.","journal-title":"Int J Oncol"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"918471","DOI":"10.1155\/2011\/918471","volume":"2011","author":"K Topfer","year":"2011","unstructured":"Topfer K, Kempe S, Muller N, et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011;2011:918471.","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"4_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.175.1.139","volume":"175","author":"S Singh","year":"1992","unstructured":"Singh S, Ross SR, Acena M, et al. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med. 1992;175(1):139\u201346.","journal-title":"J Exp Med"},{"issue":"18 Pt 1","key":"4_CR28","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1158\/1078-0432.CCR-07-0892","volume":"13","author":"TF Gajewski","year":"2007","unstructured":"Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007;13(18 Pt 1):5256\u201361.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295\u2013307.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"4_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467\u201377.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nri2742","volume":"10","author":"W Zou","year":"2010","unstructured":"Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10(4):248\u201356.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"4_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.0818-9641.2003.01151.x","volume":"81","author":"CR Parish","year":"2003","unstructured":"Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol. 2003;81(2):106\u201313.","journal-title":"Immunol Cell Biol"},{"issue":"7378","key":"4_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139.","journal-title":"Nature"},{"issue":"3","key":"4_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","volume":"14","author":"WB Coley II","year":"1891","unstructured":"Coley WB II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14(3):199\u2013220.","journal-title":"Ann Surg"},{"issue":"262","key":"4_CR36","first-page":"3","volume":"1991","author":"WB Coley","year":"1893","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop Relat Res. 1893;1991(262):3\u201311.","journal-title":"Clin Orthop Relat Res"},{"issue":"Surg Sect","key":"4_CR37","first-page":"1","volume":"3","author":"WB Coley","year":"1910","unstructured":"Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3(Surg Sect):1\u201348.","journal-title":"Proc R Soc Med"},{"issue":"6","key":"4_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2326-6066.CIR-13-0183","volume":"1","author":"American Association for Cancer Research","year":"2013","unstructured":"American Association for Cancer Research. The 2013 William B. Coley award for distinguished research in basic and tumor immunology. Cancer Immunol Res. 2013;1(6):362\u20134.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"4_CR39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1074-7613(00)80028-X","volume":"10","author":"SA Rosenberg","year":"1999","unstructured":"Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10(3):281\u20137.","journal-title":"Immunity"},{"issue":"Pt. 3","key":"4_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/hdy.1948.19","volume":"2","author":"FM Burnet","year":"1948","unstructured":"Burnet FM, Fenner F. Genetics and immunology. Heredity. 1948;2(Pt. 3):289\u2013324.","journal-title":"Heredity"},{"issue":"12","key":"4_CR41","first-page":"835","volume":"13","author":"EJ Foley","year":"1953","unstructured":"Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953;13(12):835\u20137.","journal-title":"Cancer Res"},{"issue":"6","key":"4_CR42","first-page":"769","volume":"18","author":"RT Prehn","year":"1957","unstructured":"Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957;18(6):769\u201378.","journal-title":"J Natl Cancer Inst"},{"issue":"5022","key":"4_CR43","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","volume":"1","author":"M Burnet","year":"1957","unstructured":"Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J. 1957;1(5022):779\u201386.","journal-title":"Br Med J"},{"issue":"1","key":"4_CR44","first-page":"1","volume":"17","author":"HC Outzen","year":"1975","unstructured":"Outzen HC, Custer RP, Eaton GJ, et al. Spontaneous and induced tumor incidence in germfree \"nude\" mice. J Reticuloendothel Soc. 1975;17(1):1\u20139.","journal-title":"J Reticuloendothel Soc"},{"key":"4_CR45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0065-230X(08)60179-7","volume":"22","author":"O Stutman","year":"1975","unstructured":"Stutman O. Immunodepression and malignancy. Adv Cancer Res. 1975;22:261\u2013422.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"4_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","volume":"121","author":"R Kim","year":"2007","unstructured":"Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1\u201314.","journal-title":"Immunology"},{"key":"4_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0065-230X(08)60936-7","volume":"27","author":"RB Herberman","year":"1978","unstructured":"Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res. 1978;27:305\u201377.","journal-title":"Adv Cancer Res"},{"issue":"6832","key":"4_CR48","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107\u201311.","journal-title":"Nature"},{"key":"4_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/1743-422X-10-239","volume":"10","author":"WH Gerlich","year":"2013","unstructured":"Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013;10:239.","journal-title":"Virol J"},{"key":"4_CR50","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/epirev\/mxj009","volume":"28","author":"CW Shepard","year":"2006","unstructured":"Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112\u201325.","journal-title":"Epidemiol Rev"},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","volume":"213","author":"TF Gajewski","year":"2006","unstructured":"Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131\u201345.","journal-title":"Immunol Rev"},{"issue":"2","key":"4_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/eji.200526208","volume":"36","author":"T Zhang","year":"2006","unstructured":"Zhang T, Somasundaram R, Berencsi K, et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol. 2006;36(2):457\u201367.","journal-title":"Eur J Immunol"},{"issue":"1","key":"4_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","volume":"14","author":"RJ Buckanovich","year":"2008","unstructured":"Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14(1):28\u201336.","journal-title":"Nat Med"},{"issue":"6","key":"4_CR54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1084\/jem.20041130","volume":"200","author":"MJ Turk","year":"2004","unstructured":"Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004;200(6):771\u201382.","journal-title":"J Exp Med"},{"issue":"5","key":"4_CR55","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756\u201361.","journal-title":"J Immunol"},{"issue":"2","key":"4_CR56","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","volume":"173","author":"M Viguier","year":"2004","unstructured":"Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173(2):1444\u201353.","journal-title":"J Immunol"},{"issue":"11","key":"4_CR57","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.4049\/jimmunol.171.11.5931","volume":"171","author":"N Casares","year":"2003","unstructured":"Casares N, Arribillaga L, Sarobe P, et al. CD4+\/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol. 2003;171(11):5931\u20139.","journal-title":"J Immunol"},{"issue":"5","key":"4_CR58","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","volume":"174","author":"PA Antony","year":"2005","unstructured":"Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174(5):2591\u2013601.","journal-title":"J Immunol"},{"issue":"9","key":"4_CR59","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1245\/s10434-006-9015-y","volume":"13","author":"CT Viehl","year":"2006","unstructured":"Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2006;13(9):1252\u20138.","journal-title":"Ann Surg Oncol"},{"key":"4_CR60","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1600-065X.1999.tb01331.x","volume":"170","author":"RF Wang","year":"1999","unstructured":"Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85\u2013100.","journal-title":"Immunol Rev"},{"issue":"6","key":"4_CR61","first-page":"611","volume":"25","author":"AD Chan","year":"1998","unstructured":"Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol. 1998;25(6):611\u201322.","journal-title":"Semin Oncol"},{"issue":"4","key":"4_CR62","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0167-5699(97)84664-6","volume":"18","author":"SA Rosenberg","year":"1997","unstructured":"Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997;18(4):175\u201382.","journal-title":"Immunol Today"},{"issue":"3","key":"4_CR63","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nm0398-321","volume":"4","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"4_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00008390-199602000-00003","volume":"6","author":"MJ Maeurer","year":"1996","unstructured":"Maeurer MJ, Storkus WJ, Kirkwood JM, et al. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 1996;6(1):11\u201324.","journal-title":"Melanoma Res"},{"issue":"8","key":"4_CR65","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2002.08.017","volume":"20","author":"NL Berinstein","year":"2002","unstructured":"Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol. 2002;20(8):2197\u2013207.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4_CR66","first-page":"2756","volume":"5","author":"F Wang","year":"1999","unstructured":"Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund\u2019s adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5(10):2756\u201365.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"4_CR67","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"4_CR68","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrclinonc.2009.42","volume":"6","author":"AM Eggermont","year":"2009","unstructured":"Eggermont AM. Immunotherapy: vaccine trials in melanoma\u2014time for reflection. Nat Rev Clin Oncol. 2009;6(5):256\u20138.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"4_CR69","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.4049\/jimmunol.175.9.6169","volume":"175","author":"SA Rosenberg","year":"2005","unstructured":"Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self\/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175(9):6169\u201376.","journal-title":"J Immunol"},{"issue":"4","key":"4_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00002371-200307000-00007","volume":"26","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother. 2003;26(4):349\u201356.","journal-title":"J Immunother"},{"issue":"4","key":"4_CR71","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1046\/j.1365-2796.2003.01140.x","volume":"253","author":"MA Liu","year":"2003","unstructured":"Liu MA. DNA vaccines: a review. J Intern Med. 2003;253(4):402\u201310.","journal-title":"J Intern Med"},{"issue":"9","key":"4_CR72","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1172\/JCI23467","volume":"114","author":"MA Kutzler","year":"2004","unstructured":"Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest. 2004;114(9):1241\u20134.","journal-title":"J Clin Invest"},{"issue":"2","key":"4_CR73","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1586\/14760584.7.2.175","volume":"7","author":"S Lu","year":"2008","unstructured":"Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines. 2008;7(2):175\u201391.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"4_CR74","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4_CR75","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"4_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-008-0568-4","volume":"58","author":"L Engell-Noerregaard","year":"2009","unstructured":"Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58(1):1\u201314.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"4_CR77","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nri1592","volume":"5","author":"J Banchereau","year":"2005","unstructured":"Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296\u2013306.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4_CR78","first-page":"2665","volume":"20","author":"B Bodey","year":"2000","unstructured":"Bodey B, Bodey B Jr, Siegel SE, et al. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 2000;20(4):2665\u201376.","journal-title":"Anticancer Res"},{"issue":"1","key":"4_CR79","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.25937","volume":"57","author":"CL Lai","year":"2013","unstructured":"Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57(1):399\u2013408.","journal-title":"Hepatology"},{"issue":"9686","key":"4_CR80","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301\u201314.","journal-title":"Lancet"},{"issue":"2","key":"4_CR81","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1084\/jem.156.2.454","volume":"156","author":"K Welte","year":"1982","unstructured":"Welte K, Wang CY, Mertelsmann R, et al. Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med. 1982;156(2):454\u201364.","journal-title":"J Exp Med"},{"issue":"4","key":"4_CR82","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.4049\/jimmunol.132.4.2123","volume":"132","author":"JH Donohue","year":"1984","unstructured":"Donohue JH, Rosenstein M, Chang AE, et al. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol. 1984;132(4):2123\u20138.","journal-title":"J Immunol"},{"issue":"4","key":"4_CR83","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1084\/jem.155.4.968","volume":"155","author":"MA Cheever","year":"1982","unstructured":"Cheever MA, Greenberg PD, Fefer A, et al. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med. 1982;155(4):968\u201380.","journal-title":"J Exp Med"},{"issue":"5","key":"4_CR84","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","volume":"161","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161(5):1169\u201388.","journal-title":"J Exp Med"},{"issue":"3\u20135","key":"4_CR85","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0171-2985(86)80122-X","volume":"172","author":"MT Lotze","year":"1986","unstructured":"Lotze MT, Rosenberg SA. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology. 1986;172(3\u20135):420\u201337.","journal-title":"Immunobiology"},{"issue":"3","key":"4_CR86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cyto.2004.06.010","volume":"28","author":"SL Gaffen","year":"2004","unstructured":"Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28(3):109\u201323.","journal-title":"Cytokine"},{"issue":"15","key":"4_CR87","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","volume":"19","author":"GQ Phan","year":"2001","unstructured":"Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19(15):3477\u201382.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4_CR88","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/01.cji.0000155049.26787.45","volume":"28","author":"PA Antony","year":"2005","unstructured":"Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005;28(2):120\u20138.","journal-title":"J Immunother"},{"issue":"34","key":"4_CR89","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1073\/pnas.1400472111","volume":"111","author":"S Plotkin","year":"2014","unstructured":"Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014;111(34):12283\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4_CR90","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3747\/co.2007.118","volume":"14","author":"G Fraser","year":"2007","unstructured":"Fraser G, Smith CA, Imrie K, et al. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol. 2007;14(3):96\u2013109.","journal-title":"Curr Oncol"},{"issue":"16","key":"4_CR91","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMe058196","volume":"353","author":"GN Hortobagyi","year":"2005","unstructured":"Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005;353(16):1734\u20136.","journal-title":"N Engl J Med"},{"issue":"14","key":"4_CR92","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"issue":"2","key":"4_CR93","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1358\/dot.2004.40.2.799423","volume":"40","author":"TE Witzig","year":"2004","unstructured":"Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin\u2019s lymphoma. Drugs Today (Barc). 2004;40(2):111\u20139.","journal-title":"Drugs Today (Barc)"},{"issue":"17","key":"4_CR94","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","volume":"20","author":"L Amiri-Kordestani","year":"2014","unstructured":"Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436\u201341.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4_CR95","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299\u2013308.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4_CR96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","volume":"39","author":"M Kalos","year":"2013","unstructured":"Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49\u201360.","journal-title":"Immunity"},{"issue":"Suppl 1","key":"4_CR97","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/jcp.1030500416","volume":"50","author":"NA Mitchison","year":"1957","unstructured":"Mitchison NA. Adoptive transfer of immune reactions by cells. J Cell Physiol Suppl. 1957;50(Suppl 1):247\u201364.","journal-title":"J Cell Physiol Suppl"},{"issue":"2","key":"4_CR98","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1084\/jem.159.2.495","volume":"159","author":"A Mazumder","year":"1984","unstructured":"Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984;159(2):495\u2013507.","journal-title":"J Exp Med"},{"issue":"8","key":"4_CR99","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/archsurg.1975.01360140052011","volume":"110","author":"D Murray","year":"1975","unstructured":"Murray D, Hreno A, Dutton J, et al. Prognosis in colon cancer: a pathologic reassessment. Arch Surg. 1975;110(8):908\u201313.","journal-title":"Arch Surg"},{"issue":"51","key":"4_CR100","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"4_CR101","first-page":"3491","volume":"58","author":"Y Naito","year":"1998","unstructured":"Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491\u20134.","journal-title":"Cancer Res"},{"issue":"4770","key":"4_CR102","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318\u201321.","journal-title":"Science"},{"issue":"4","key":"4_CR103","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","volume":"26","author":"ME Dudley","year":"2003","unstructured":"Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332\u201342.","journal-title":"J Immunother"},{"issue":"4","key":"4_CR104","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","volume":"155","author":"RJ North","year":"1982","unstructured":"North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155(4):1063\u201374.","journal-title":"J Exp Med"},{"issue":"25","key":"4_CR105","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u201380.","journal-title":"N Engl J Med"},{"issue":"32","key":"4_CR106","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4_CR107","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/cncr.28547","volume":"120","author":"J Tseng","year":"2014","unstructured":"Tseng J, Citrin DE, Waldman M, et al. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014;120(9):1426\u201332.","journal-title":"Cancer"},{"issue":"10","key":"4_CR108","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.4049\/jimmunol.175.10.7046","volume":"175","author":"J Zhou","year":"2005","unstructured":"Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175(10):7046\u201352.","journal-title":"J Immunol"},{"issue":"8","key":"4_CR109","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","volume":"31","author":"KQ Tran","year":"2008","unstructured":"Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31(8):742\u201351.","journal-title":"J Immunother"},{"issue":"2","key":"4_CR110","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/CJI.0b013e318209c94c","volume":"34","author":"O Itzhaki","year":"2011","unstructured":"Itzhaki O, Hovav E, Ziporen Y, et al. Establishment and large-scale expansion of minimally cultured \"young\" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011;34(2):212\u201320.","journal-title":"J Immunother"},{"issue":"24","key":"4_CR111","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","volume":"16","author":"ME Dudley","year":"2010","unstructured":"Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched \"young\" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16(24):6122\u201331.","journal-title":"Clin Cancer Res"},{"issue":"6184","key":"4_CR112","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641\u20135.","journal-title":"Science"},{"issue":"1","key":"4_CR113","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ymthe.2004.04.014","volume":"10","author":"C Rossig","year":"2004","unstructured":"Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004;10(1):5\u201318.","journal-title":"Mol Ther"},{"issue":"5796","key":"4_CR114","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126\u20139.","journal-title":"Science"},{"issue":"11","key":"4_CR115","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.4049\/jimmunol.1000189","volume":"184","author":"TL Frankel","year":"2010","unstructured":"Frankel TL, Burns WR, Peng PD, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol. 2010;184(11):5988\u201398.","journal-title":"J Immunol"},{"issue":"3","key":"4_CR116","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535\u201346.","journal-title":"Blood"},{"issue":"4","key":"4_CR117","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1177\/0194599812448356","volume":"147","author":"BJ Seaman","year":"2012","unstructured":"Seaman BJ, Guardiani EA, Brewer CC, et al. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg. 2012;147(4):744\u20139.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"7","key":"4_CR118","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4_CR119","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133\u201351.","journal-title":"J Immunother"},{"issue":"3","key":"4_CR120","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0198-8859(99)00155-X","volume":"61","author":"JM Ellis","year":"2000","unstructured":"Ellis JM, Henson V, Slack R, et al. Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231. Hum Immunol. 2000;61(3):334\u201340.","journal-title":"Hum Immunol"},{"issue":"2","key":"4_CR121","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","volume":"21","author":"M Sadelain","year":"2009","unstructured":"Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215\u201323.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"4_CR122","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689\u2013702.","journal-title":"J Immunother"},{"issue":"6","key":"4_CR123","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"177","key":"4_CR124","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.","journal-title":"Sci Transl Med"},{"issue":"16","key":"4_CR125","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"4","key":"4_CR126","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther"},{"key":"4_CR127","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1600-065X.2008.00602.x","volume":"222","author":"I Marigo","year":"2008","unstructured":"Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162\u201379.","journal-title":"Immunol Rev"},{"issue":"5","key":"4_CR128","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","volume":"30","author":"EM Shevach","year":"2009","unstructured":"Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636\u201345.","journal-title":"Immunity"},{"issue":"8","key":"4_CR129","doi-asserted-by":"publisher","first-page":"e25961","DOI":"10.4161\/onci.25961","volume":"2","author":"C Devaud","year":"2013","unstructured":"Devaud C, John LB, Westwood JA, et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013;2(8):e25961.","journal-title":"Oncoimmunology"},{"key":"4_CR130","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/1471-2407-10-464","volume":"10","author":"JD Veltman","year":"2010","unstructured":"Veltman JD, Lambers ME, van Nimwegen M, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:464.","journal-title":"BMC Cancer"},{"issue":"2","key":"4_CR131","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2567.2010.03357.x","volume":"132","author":"IN Buhtoiarov","year":"2011","unstructured":"Buhtoiarov IN, Sondel PM, Wigginton JM, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011;132(2):226\u201339.","journal-title":"Immunology"},{"issue":"12","key":"4_CR132","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691\u2013702.","journal-title":"J Exp Med"},{"key":"4_CR133","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","volume":"16","author":"MK Gately","year":"1998","unstructured":"Gately MK, Renzetti LM, Magram J, et al. The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495\u2013521.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"4_CR134","doi-asserted-by":"publisher","first-page":"e0119483","DOI":"10.1371\/journal.pone.0119483","volume":"10","author":"SJ Blake","year":"2015","unstructured":"Blake SJ, Ching AL, Kenna TJ, et al. Blockade of PD-1\/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS One. 2015;10(3):e0119483.","journal-title":"PLoS One"},{"issue":"2","key":"4_CR135","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CJI.0000000000000064","volume":"38","author":"DA Mahvi","year":"2015","unstructured":"Mahvi DA, Meyers JV, Tatar AJ, et al. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. J Immunother. 2015;38(2):54\u201361.","journal-title":"J Immunother"},{"key":"4_CR136","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565\u201394.","journal-title":"Annu Rev Immunol"},{"key":"4_CR137","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"5256","key":"4_CR138","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"8","key":"4_CR139","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"2","key":"4_CR140","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122\u201333.","journal-title":"N Engl J Med"},{"issue":"26","key":"4_CR141","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"8","key":"4_CR142","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1177\/1060028015586218","volume":"49","author":"MS Barbee","year":"2015","unstructured":"Barbee MS, Ogunniyi A, Horvat TZ, et al. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015;49(8):907\u201337.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"4_CR143","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2217\/imt.13.102","volume":"5","author":"RZ Panni","year":"2013","unstructured":"Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy. 2013;5(10):1075\u201387.","journal-title":"Immunotherapy"},{"issue":"3","key":"4_CR144","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"}],"container-title":["Advances in Experimental Medicine and Biology","Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-67577-0_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T15:06:21Z","timestamp":1720019181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-67577-0_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319675756","9783319675770"],"references-count":144,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-67577-0_4","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"24 December 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}